- Home
- PLBL vs SRPT Comparison
PLBL vs SRPT Comparison
Compare PLBL & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBL | SRPT |
|---|---|---|
| Founded | 2021 | 1980 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2024 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PLBL | SRPT |
|---|---|---|
| Price | $7.25 | $16.08 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 24 |
| Target Price | N/A | ★ $21.77 |
| AVG Volume (30 Days) | 143.8K | ★ 2.3M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.10 | $14.68 |
| 52 Week High | $11.75 | $24.68 |
Technical Indicators
Market Signals| Indicator | PLBL | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 74.62 | 37.62 |
| Support Level | $5.26 | $15.19 |
| Resistance Level | $7.23 | $18.26 |
| Average True Range (ATR) | 0.34 | 0.92 |
| MACD | 0.12 | -0.23 |
| Stochastic Oscillator | 84.38 | 2.48 |
Price Performance
Historical ComparisonAbout PLBL Polibeli Group Ltd Class A Ordinary Shares
Polibeli Group Ltd is a holding company without any business operations. It provides digital supply chain services and distribution sales through subsidiaries in a number of countries around the globe. Currently, its business is mainly in Japan and Indonesia, while also having business operations in some international locations, including Hong Kong, Europe, and Others. The single reportable segment contains product revenues derived from world-wide goods trading, and service revenues that are ancillary to world-wide goods trading business.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.